Original Article
Apoptosis of human hepatocellular carcinoma cells SMMC-7721 induced by C-3 methyldiene thiazolidinedione acetic acid

Hong-Xia Liang1, Yi-Hua Yu1, Xiao-Hua Li1, Nai-Fu Tang1, Guo-Qiang Hu2, Bin Liu1

1Institute of Nursing and Health, Henan University, Kaifeng, Henan, China; 2College of Pharmacy, Henan University, Kaifeng, Henan, China

Received July 9, 2018; Accepted September 12, 2018; Epub January 15, 2019; Published January 30, 2019

Abstract: Objective: The objective of this study was to investigate the effect of rufloxacin derivative C-3 methyldiene thiazolidinedione acetic acid on apoptosis of human hepatocellular carcinoma cells SMMC-7721. Methods: Human hepatocellular carcinoma cells SMMC-7721, esophageal cancer cells EC-9706, colon cancer CaCO-2 cells, and hepatocytes L-02 were cultured in vitro with various concentrations of 6-fluoro -7-(4-methylpiperazin-1-yl)-8, 1-(sulfolatosyl)-1,4-dihydro-4-oxo-3-(3-carboxymethyl-2, 4-thiazolidinedione- 5-methylidene) quinoline (R16). MTT assay was used to detect the inhibitory effect of R16 on proliferation in all cell lines. DAPI fluorescent staining and TUNEL assay were used to detect the changes of apoptosis. PI staining and flow cytometry were used to detect cell cycle changes. p53 and caspase-3 protein expression levels were detected by Western blot. Results: R16 significantly inhibited cell proliferation of SMMC-7721, EC-9706 and CaCO-2 cells under the concentration of 2-20 µmol·L−1. The 24 hour IC50 values were 3.912, 4.215 and 3.380 mol·L−1, respectively. The 24 hour IC50 value of L-02 cells was 35.224 µmol·L−1. The 24 hour IC50 value of rufloxacin was 226.924 µmol·L−1 for SMMC-7721. The 24 hour IC50 value of sunitinib was 7.846 µmol·L−1 for SMMC-7721. Following R16 treatment, cell cycle of SMMC-7721 was arrested at G1-S phase and the apoptosis rate was significantly higher compared to the control group (P<0.05). R16 significantly increased p53 and caspase-3 expression in SMMC-7721 cells. In addition, the active fragment of caspase-3 was significantly increased. Conclusions: Rufloxacin-rhodanine derivatives exhibited a selective inhibitory effect on cancer cells and significantly induced apoptosis of human hepatocellular carcinoma cells SMMC-7721.

Keywords: Rufloxacin-Rhodanine derivatives, hepatocellular carcinoma cells, cell proliferation, apoptosis, cell cycle

Introduction
Quinolones are widely used as anti-infective agents in clinical practice [1]. This type of agents are inhibitors of DNA gyrase, a type II DNA topoisomerase [2]. The acting mechanism of this enzyme is to perform DNA strands cleavage, change DNA topological structures and reconnect the structures. The enzyme plays an important role in DNA replication, transcription and repair [3]. In eukaryotic cells, some sequence fragments of topoisomerase II have a high degree of homology with DNA gyrase [4]. Some of the fluoroquinolones carboxylic acids commonly used in clinical application, such as ciprofloxacin, rufloxacin, and ofloxacin, have a mild inhibitory effect on eukaryotic topoisomerase II activity [5]. Therefore, quinolone antibacterics with effective structure modifications are expected to become a novel class of anti-cancer candidate compounds. It has been reported that following structure modifications, most anti-cancer fluoroquinolone compounds are topoisomerase II toxins and able to kill tumor cells by stabilizing topoisomerase II mediated cleavable complex to block the connection of DNA double strands, similar to the role of doxorubicin in clinical application [6]. The mechanism of action is mainly associated with inhibition of DNA topoisomerase II activity and induction of apoptosis [7, 8]. In the beginning the modification on anti-bacterial fluoroquinolones was focused on the structure modification on N-1 and C-7 of quinoline ring, and polycyclic quinolone derivatives with anti-cancer
activity were synthesized. However, these compounds failed prior to clinical evaluation due to their in vivo toxicity, low bioavailability and inability to be metabolized [9]. The carboxyl group on C-3 of fluoroquinolone carboxylic acid is required for anti-bacterial activity but has no effect on anti-cancer activity [10]. The five-membered azole heterocyclic ring has been used as a backbone with dominant pharmacophores in the design of drug molecules, among which thiazolidinediones have gained a lot of attention due to their pharmacological activities. Based on the research of fluoroquinolone C-3 rhodanine unsaturated ketones, according to isosteres and splicing principles, thiazolidinedione was used, instead of thio-thiazolidinedione, as the isostere of fluoroquinolones C-3 carboxyl group. A series of fluoroquinolone derivatives were designed and synthesized with good solubility, low molecular weight, unsaturated ketone structures and similar structures to of chalcones and tyrosine kinase inhibitor sunitinib. The anti-tumor activity of this type of compounds was screened. The results showed that this type of derivatives all had good anti-tumor activity. Among these compounds, 6-fluoro-7-(4-methylpiperazin-1-yl)-8,1-(thioethylene)-1,4-dihydro-4-oxo-3-[5-(3-carboxymethyl-2,4-thiazolidinedione) ylidene]-quinoline (R16) exhibited the strongest activity, with an $IC_{50}$ up to 3.912 µmol/L and further research and development value (Figure 1).

Materials and methods

Main reagents and instruments

**Inducer:** Rufloxacin derivative C-3 methylidene thiazolidinedione acetic acid was designed and synthesized by the Institute of Chemical Biology of Henan University. The agent was dissolved in dimethyl sulfoxide (DMSO, Solarbio Co.) at a beginning concentration of $1 \times 10^{-2} \text{ mol·L}^{-1}$.

**Cell lines and major reagents**

Human hepatocellular carcinoma cells SMMC-7721 and human esophageal cancer cells EC-9706 were cultured in DMEM media (Gibco) containing fetal bovine serum (Hangzhou Four Seasons Bioengineering Material Inc.) at a concentration of 0.1% (v/v). Colon cancer CaCO-2 cells and hepatocytes L-02 were cultured in RPMI-1640 media (Gibco) containing fetal bovine serum at a concentration of 0.1% (v/v). Cells were placed in an incubator with 0.05% (v/v) CO$_2$ at 37°C. Tetramethyl azolium salt (mTT) was purchased from Solarbio Co. DAPI was purchased from Sigma. DeadEnd™ Fluorometric TUNEL System was purchased from Promega. Mouse monoclonal anti-casepase-3 antibody was purchased from Novus. Rabbit polyclonal anti-p53 antibody was purchased from Baiqi Co. Mouse anti-β-actin polyclonal antibody was purchased from Zhongshan Jingqiao Co. HRP-labeled goat anti-rabbit and goat anti-mouse antibodies were purchased from Santa Cruz Co. The remaining reagents were domestic analytical reagents.

**Major equipment**

The CO$_2$ incubator (Forma 3121) and plate reader (Multiskan Ascent) were purchased from Thermo. The inverted microscope was purchased from Leica Microsystems. BX51 fluorescent microscope was provided by Olympus. High speed centrifuge was purchased from Eppendorf. Gel imaging system was purchased from UVP, LLC. Flow cytometer was provided by AceaBio Co. Electrophoresis and semi-dry blotting membrane transfer system were purchased from Six-One Electronic Equipment Manufacturing.

**Methods**

**Effects of drugs on cell proliferation by MTT assay:** Cells were inoculated on a 96-well plate at a concentration of $16 \times 10^3 \text{ L}^{-1}$. Various concentrations of R16 was added to the culture and the media was removed after 24, 48, 72 hour treatment. 0.15 ml DMSO was added to each well. The plate was shaken for 8 minutes and the absorbance at 570 nm was detected in
Figure 2. Proliferation inhibition effect of R16, Rufloxacin, and Sunitinib on human cancer cells and L-02 cells. SMMC-7721 cells (A), EC-9706 cells (B), CaCO-2 cells (C) and L-02 (D) cells were treated with various concentration of R16 for 24-72 hours. SMMC-7721 cells were treated with various concentration of Rufloxacin (E) and Sunitinib (F) for 24-72 hours.

The absorbance of wells containing no cells but the same volume of culture media and DMSO was used as control.

Cell Growth Inhibition Rate = \[1-(\text{OD value of treated group} - \text{OD value of control group})/(\text{OD value of untreated group} - \text{OD value of control group})\] × 100%.

Observation of cell morphological changes by DAPI staining
Cells were inoculated at a concentration of \(4 \times 10^7\)·\(L^{-1}\) in the 6-well plate where cover slides were placed at the bottom of wells. After cell adhesion, various concentrations of R16 was added and cultured for 24 hours. Cells were washed twice by PBS and fixed in paraformaldehyde for 20 minutes. 20 μl DAPI working solution was added on the cover slides. After 10 minute staining at room temperature, slides were washed three times by PBS, blocked by 78% neutral glycerol, and observed under the fluorescent microscope.

The apoptosis rate determined by TUNEL assay
Cells were inoculated at a concentration of \(4 \times 10^7\)·\(L^{-1}\) in the 6-well plate where cover slides were placed at the bottom of wells. Various concentrations of R16 was added and cultured for 24 hours. TUNEL assay was performed following the kit instruction from Promega and the apoptosis rate was calculated.

Observation of cell cycle flow cytometry with PI staining
Cells were inoculated in a cell flask at a concentration of \(1 \times 10^9\)·\(L^{-1}\) and cultured for 12 hours. Various concentrations of R16 was added and cultured for 24 hours. Cells were collected into an EP tube, washed once by PBS, fixed by 70% ethanol, washed by PBS once and stained by PI for 30 minutes in the dark at room temperature. Cells were detected by flow cytometry.

Detection of protein expression by western blot
Cells were treated by various concentrations of R16 for 24 hours. 200 μL RIPA lysis buffer was added to thoroughly lyse cells. Cells were centrifuged at 4°C (12000 r·min\(^{-1}\)) for 5 minutes for protein extraction. Protein concentration was detected by Coomassie blue and G250 spectrophotometer. Protein samples were subjected to 12% SDS-PAGE and transferred to PVDF membrane. The membrane was blocked in 5% fat free milk for 1 hour, incubated overnight with the primary antibody at 4°C and then with the secondary antibody for 1 h. Results were shown by chemiluminescence and analyzed by gel imaging system.
The effect of e16 on SMMC-7721 cell cycle pattern

SMMC-7721 cells were treated by R16 at a concentration of 2.543 µmol·L⁻¹, 3.912 µmol·L⁻¹, and 5.427 µmol·L⁻¹, respectively, for 24 hours. Compared with the control group, p53 expression was significantly increased following R16 treatment, in a concentration dependent manner. Caspase-3 expression was increased, indicating apoptosis induction by R16.

Induction of SMMC-7721 apoptosis by R16

The results of DAPI staining showed that after 24 hour treatment of R16, SMMC-7721 cells exhibited apoptotic morphological changes, including nuclear fragmentation and dissolution, and chromatin condensation, shrinkage, and marginalization. TUNEL assay results showed that with an increasing concentration of R16, apoptotic cells were significantly increased in a concentration dependent manner, as shown in Figure 4 and Table 1.

Statistical analysis

Data were analyzed by EXCEK and SPSS 17.0 software. Quantitative data are expressed using $\bar{x} \pm s$. Comparisons between groups were analyzed by t-test.

Results

Inhibition of proliferation of various types of cells by R16

SMMC-7721, EC-9706, and CaCO-2 cells were treated by various concentrations of R16 for 24, 48, and 72 hours, respectively. R16 exhibited a substantial inhibitory effect on proliferation of cancer cells in a time and concentration dependent manner. The IC₅₀ values for 24 hour treatment were 3.912 µmol·L⁻¹ ($r^2=0.8293$), 4.215 µmol·L⁻¹ ($r^2=0.8926$) and 3.380 µmol·L⁻¹ ($r^2=0.9568$), respectively. L-02 cells were treated by R16 for 24, 48, and 72 hours, and failed to show significant inhibitory effect on cell proliferation. The IC₅₀ value for 24 hour treatment was 35.224 µmol·L⁻¹ ($r^2=0.9287$). The synthetic raw material of R16, rufloxacin had no significant inhibitory effect on SMMC-7721 proliferation, with a 24 hour IC₅₀ of 226.924 µmol·L⁻¹ ($r^2=0.7981$). Sunitinib significantly inhibited SMMC-7731 proliferation, with a IC₅₀ value of 7.46 µmol·L⁻¹ ($r^2=0.9650$), significantly higher than that of R16 on SMMC-7721 cells (Figure 2).

The effect of e16 on SMMC-7721 cell cycle pattern

SMMC-7721 cells were treated by R16 at a concentration of 2.543 µmol·L⁻¹, 3.912 µmol·L⁻¹, and 5.427 µmol·L⁻¹, respectively, for 24 hours. Compared with the control group, R16 treated group showed significantly increased number of cells at G₀/G₁ phase ($P=0.011$, 0.001, and <0.001), no significant changes of cell number at S phase ($P=0.054$, 0.906, and 0.683), significantly decreased number of cells at G₂/M phase ($P=0.024$, <0.001, and <0.001), and significantly increased number of cells at Sub-G₁ phase ($P=0.031$, 0.001 and <0.001). These results showed that R16 arrested SMMC-7721 cell cycle at c-S phase, and inhibited cell division and proliferation, as shown in Figure 5.

The effect of R16 on cellular p53 and caspase-3 expression

SMMC-7721 were treated by R16 at a concentration of 2.543 µmol·L⁻¹, 3.912 µmol·L⁻¹, and 5.427 µmol·L⁻¹, respectively, for 24 hours. p53 and caspase-3 protein expression levels were detected by Western blot. Compared with the control group, p53 expression was significantly increased following R16 treatment, in a concentration dependent manner. Caspase-3 ex-
Expression was also increased, as well as active fragments (Figure 6).

**Discussion**

In this study, the anti-cancer unsaturated ketone skeleton of rhodanine was assembled with fluoroquinolone skeleton at the C-3 position to construct a series of target compounds of amide fluoroquinolones (rhodanine unsaturated ketone). MTT assay was used to screen the target compounds. Twelve fluoroquinolone-rhodanine derivatives had an IC$_{50}$ below 50 μmol·L$^{-1}$ after 24 hour treatment on human hepatocellular carcinoma cells SMMC-7721. Among these derivatives, the IC$_{50}$ of R16 was 3.893 μmol·L$^{-1}$, which was significantly lower than that of the parent compound rufloxacin (226.924 μmol·L$^{-1}$), and also lower than that of the clinical anti-cancer agent sunitinib (7.846 μmol·L$^{-1}$). This results indicate that it was worthy further research and development to investigate rufloxacin-rhodanine derivatives, which were constructed by assembling rufloxacin and rhodanine unsaturated ketone skeleton, as anti-cancer agents.

In order to understand the difference of R16 on various cancer cells, three types of cancer cells lines (human hepatocellular carcinoma cells SMMC-7721, esophageal cancer cells EC-9706, and colon cancer CaCO-2 cells) were investigated in this study to detect the inhibitory effect of R16 on cell growth. The results show that R16 exhibited a significantly inhibitory effect on proliferation of various types of cancer cells. This effect was shown in a time and concentration dependent manner. In this study hepatocyte cell line L-02 was also cultured in vitro to detect inhibitory effect of R16 on cell growth. The IC$_{50}$ on L-02 was 35.244 μmol·L$^{-1}$, significantly higher than that of R16 on SMMC-7721 cells. This suggested the selectivity of R16 on cancer cells and possibly less toxic effects in its future use in clinical practice.

The preliminary experiments of this study demonstrate that the significant anti-cancer activity of fluoroquinolone derivatives with modified C-3 carboxyl group was mainly exhibited on DNA topoisomerase II, by inhibiting the activity of DNA topoisomerase II activity and interfering with DNA replication [11, 12]. This study detected the changes of SMMC-7721 cell cycle...
Human hepatocellular carcinoma SMMC-7721 cells

Figure 5. Effect of R16 on the cell cycle distribution in SMMC-7721 cells. Cell cycle distribution was demonstrated by Flow cytometry analysis in SMMC-7721 cells after treatment with 0 (A), 2.543 (B), 3.912 (C) and 5.427 μmol·L$^{-1}$ (D) R16 respectively for 24 hours.

Figure 6. Effects of R16 on p53 and caspase-3 protein expression in SMMC-7721 cells. 1: Control; 2: R16 (2.543 μmol·L$^{-1}$); 3: R16 (3.912 μmol·L$^{-1}$); 4: R16 (5.427 μmol·L$^{-1}$).

following R16 treatment by PI staining and flow cytometry. The results show that, compared with the control group, the cell number at $G_0/G_1$ phase was significantly increased, accompanied by decreased cell number at $G_2/M$ phase and no change in $S$ phase, indicating that cell cycle was arrested at $G_1$-$S$ phase. This change was associated with DNA replication. DNA topoisomerase II is able to catalyze the mutual transformation of DNA topological isomers, catalyze the disconnection and binding of DNA double strands, and promote DNA helix unwinding to complete the replication process [13]. DNA topoisomerase II toxin led to irreversible broken DNA and damage. The action may activate p53 protein and induce apoptosis [14, 15]. In our experiments, changes of p53 expression were detected by Western-blot. The results suggest that R16 killed SMMC-7721 by DNA damage, and enhanced p53 expression and induction of the apoptotic pathway. The changes in nuclear morphology in SMMC-7721 cells were observed by DAPI staining. Apoptotic SMMC-7721 cells were increased following 24 hour treatment of R16, shown by changes in nuclear morphology including nucleus shrinkage and fragmentation, chromatin condensation, marginalization, and appearance of apoptotic bodies [16]. TUNEL assay showed significantly enhanced caspase-3 expression and cleavage fragments with the increased R16 concentration. The results indicate that R16 induced apoptosis by activating capase-3 pathway.

In summary, modified rufloxacin-rhodanine derivatives arrested cell cycle at $G_1$-$S$ phase, and significantly inhibited division and proliferation of cancer cells, such as hepatocellular carcinoma cells, in a selective manner. The anticancer effect of R16 was mainly accomplished by induction of apoptosis [17].

Acknowledgements

This work was supported by the National Natural Science Foundation of China (2107-2045) and Henan Natural Science Foundation (112102310307).

Disclosure of conflict of interest

None.

Address correspondence to: Bin Liu, Institute of Nursing and Health, Henan University, Jin Ming Avenue, College of Nursing and Health, Kaifeng 475004, China. Tel: +86- 371-23880399; Fax: +86-371-23880399; E-mail: byx0552@163.com

References


